Effect of Inhaled Corticosteroid on Exercise-Induced Asthma
Effect of Inhaled Corticosteroid on Exercise-Induced Asthma
Subbarao P, Duong M, Adelroth E, et al
J Allergy Clin Immunol. 2006;117:1008-1013
This study investigated the effect of 4 different doses of an inhaled corticosteroid (ICS), ciclesonide, on lung function following a standardized exercise challenge in 26 asthmatics, with a double-blind, randomized, crossover study design. Patients had to have a baseline forced expiratory volume in 1 second (FEV1) of at least 70% predicted, and their primary outcome was the maximum percentage decrease in FEV1 after exercise challenge.
The doses of ciclesonide used were 40 mcg and 160 mcg as well as 80 mcg and 320 mcg. The study found that the lower doses of ICS (40 mcg and 80 mcg) provided some protection against exercise-induced asthma by the end of week 1; patients who had received this dosage had a 9% reduction in the maximum decrease in FEV1. They did not experience any increasing protection with longer treatment at that dose. In contrast, patients who had been treated with 160 mcg and 320 mcg of ciclesonide had an 8.7% reduction in their maximal decrease in their FEV1 with exercise, as well as well as a linear increase in protection from exercise-induced asthma over the 3-week duration of the study. Patients who had received 320 mcg ciclesonide achieved a 51.1% reduction in their maximal decrease in FEV1 following exercise.
The study authors concluded that there was a significant improvement in exercise-induced bronchospasm (EIB) at all doses of ciclesonide, but that treatment with the higher doses of that medication (160 mcg and 320 mcg) resulted in continuing improvement in FEV1 over time. Furthermore, they saw no plateau in the protective effect of the ICS over the 3 weeks of the study.
Subbarao P, Duong M, Adelroth E, et al
J Allergy Clin Immunol. 2006;117:1008-1013
This study investigated the effect of 4 different doses of an inhaled corticosteroid (ICS), ciclesonide, on lung function following a standardized exercise challenge in 26 asthmatics, with a double-blind, randomized, crossover study design. Patients had to have a baseline forced expiratory volume in 1 second (FEV1) of at least 70% predicted, and their primary outcome was the maximum percentage decrease in FEV1 after exercise challenge.
The doses of ciclesonide used were 40 mcg and 160 mcg as well as 80 mcg and 320 mcg. The study found that the lower doses of ICS (40 mcg and 80 mcg) provided some protection against exercise-induced asthma by the end of week 1; patients who had received this dosage had a 9% reduction in the maximum decrease in FEV1. They did not experience any increasing protection with longer treatment at that dose. In contrast, patients who had been treated with 160 mcg and 320 mcg of ciclesonide had an 8.7% reduction in their maximal decrease in their FEV1 with exercise, as well as well as a linear increase in protection from exercise-induced asthma over the 3-week duration of the study. Patients who had received 320 mcg ciclesonide achieved a 51.1% reduction in their maximal decrease in FEV1 following exercise.
The study authors concluded that there was a significant improvement in exercise-induced bronchospasm (EIB) at all doses of ciclesonide, but that treatment with the higher doses of that medication (160 mcg and 320 mcg) resulted in continuing improvement in FEV1 over time. Furthermore, they saw no plateau in the protective effect of the ICS over the 3 weeks of the study.
